Revenue growth remains cyclically uneven, with quarterly performance ranging from a 0.8% contraction in 2024Q1 to a 9.8% expansion in 2023Q4, while operating margins have struggled to stabilize above 14.2% as of 2026Q1.
| Sales/Revenue | 1.2B | 1.14B | 1.1B | 1.09B | 983.68M | 843.92M | 662.04M | 536.54M |
| Revenue Growth % | 6.7% | 3.21% | 1.72% | 10.34% | 16.56% | 27.47% | 23.39% | - |
| Cost of Goods Sold | 851.87M | 809.15M | 801.72M | 745.46M | 663.88M | 578.51M | 467.86M | 398.52M |
| COGS % of Revenue | - | 71.01% | 72.62% | 68.68% | 67.49% | 68.55% | 70.67% | 74.28% |
| Gross Profit | 348.16M | 330.33M | 302.32M | 339.89M | 319.8M | 265.4M | 194.18M | 138.02M |
| Gross Margin % | 29.01% | 28.99% | 27.38% | 31.32% | 32.51% | 31.45% | 29.33% | 25.72% |
| Gross Profit Growth % | - | 9.26% | -11.05% | 6.28% | 20.5% | 36.68% | 40.69% | - |
| Operating Expenses | 149.36M | 147.25M | 141.18M | 139.17M | 127.37M | 103.18M | 91.07M | 75.8M |
| OpEx % of Revenue | - | 12.92% | 12.79% | 12.82% | 12.95% | 12.23% | 13.76% | 14.13% |
| Selling, General & Admin | 127.07M | 122.85M | 118.6M | 113.92M | 111.83M | 82.95M | 78.91M | 76.71M |
| SG&A % of Revenue | - | 10.78% | 10.74% | 10.5% | 11.37% | 9.83% | 11.92% | 14.3% |
| Research & Development | 25.28M | 24.4M | 31.67M | 35.67M | 34.39M | 29.62M | 17.39M | 7.83M |
| R&D % of Revenue | - | 2.14% | 2.87% | 3.29% | 3.5% | 3.51% | 2.63% | 1.46% |
| Other Operating Expenses | -1.27M | 0 | -9.09M | -10.42M | -18.85M | -9.39M | -5.23M | -8.74M |
| Operating Income | 198.8M | 183.08M | 161.14M | 200.72M | 192.43M | 162.22M | 103.11M | 62.22M |
| Operating Margin % | 16.57% | 16.07% | 14.6% | 18.49% | 19.56% | 19.22% | 15.57% | 11.6% |
| Operating Income Growth % | - | 13.61% | -19.72% | 4.31% | 18.62% | 57.33% | 65.72% | - |
| EBITDA | 291.17M | 268.18M | 241.79M | 279.2M | 257.25M | 218.61M | 157.21M | 108.44M |
| EBITDA Margin % | 24.26% | 23.54% | 21.9% | 25.72% | 26.15% | 25.9% | 23.75% | 20.21% |
| EBITDA Growth % | -0.49% | 10.91% | -13.4% | 8.53% | 17.68% | 39.05% | 44.98% | - |
| D&A (Non-Cash Add-back) | 92.37M | 85.1M | 80.65M | 78.48M | 64.82M | 56.38M | 54.1M | 46.22M |
| EBIT | 198.09M | 183.08M | 167.15M | 193.87M | 191.58M | 170.54M | 102.27M | 60.32M |
| Net Interest Income | -8.19M | -9.32M | -5.14M | -3.52M | -3.29M | -4.32M | -6.37M | -5.1M |
| Interest Income | 1.01M | 12.49M | 1.72M | 792K | 648K | 548K | 424.07K | 195.87K |
| Interest Expense | 9.2M | 21.8M | 6.86M | 4.32M | 3.94M | 4.87M | 6.79M | 5.3M |
| Other Income/Expense | -6.14M | -1.44M | -854K | -11.17M | -4.79M | 3.45M | -6.83M | -7.51M |
| Pretax Income | 192.66M | 181.64M | 160.29M | 189.55M | 187.64M | 165.67M | 96.28M | 54.71M |
| Pretax Margin % | 16.05% | 15.94% | 14.52% | 17.46% | 19.08% | 19.63% | 14.54% | 10.2% |
| Income Tax | 51.71M | 47.35M | 42.52M | 43.86M | 44.63M | 31.4M | 17.68M | 16.01M |
| Effective Tax Rate % | 26.84% | 26.07% | 26.53% | 23.14% | 23.78% | 18.96% | 18.37% | 29.26% |
| Net Income | 140.95M | 134.28M | 117.78M | 145.63M | 142.85M | 134.32M | 78.51M | 39.2M |
| Net Margin % | 11.75% | 11.78% | 10.67% | 13.42% | 14.52% | 15.92% | 11.86% | 7.31% |
| Net Income Growth % | 12.33% | 14.01% | -19.13% | 1.95% | 6.35% | 71.08% | 100.28% | - |
| Net Income (Continuing) | 140.94M | 134.28M | 117.77M | 145.69M | 143.02M | 134.27M | 78.6M | 38.71M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 36K | 37.98K | 46K | 115K | -220K | -415K | -355K | -50K |
| EPS (Diluted) | 0.52 | 0.49 | 0.43 | 0.55 | 0.53 | 0.53 | 0.28 | 0.15 |
| EPS Growth % | 9.54% | 13.95% | -21.82% | 3.77% | 0% | 89.29% | 86.67% | - |
| EPS (Basic) | - | 0.49 | 0.43 | 0.55 | 0.53 | 0.53 | 0.28 | 0.15 |
| Diluted Shares Outstanding | 273.02M | 273M | 272.88M | 264.98M | 264.7M | 264.7M | 264.7M | 264.7M |
| Basic Shares Outstanding | 273M | 273M | 272.87M | 264.95M | 264.7M | 264.7M | 264.7M | 264.7M |
| Dividend Payout Ratio | - | 10.54% | 12.27% | 9.82% | 9.45% | 8.34% | 11.34% | 15.74% |
Energy cost volatility exposure
According to the provided income statement data, STVN's quarterly revenue growth has fluctuated significantly, ranging from a contraction of 0.8% in 2024Q1 to a peak growth of 9.8% in 2023Q4, reflecting the inherent lumpiness of project-based engineering milestones alongside more stable biopharmaceutical containment demand.
The revenue trajectory appears heavily influenced by the timing of large-scale engineering projects, which can mask the underlying performance of the recurring BDS segment. Investors should monitor whether the recent 6.6% growth in 2026Q1 represents a sustainable baseline or if the company remains susceptible to the lumpy recognition patterns typical of its industrial automation business.
As reported in financial statements, STVN's gross margin has oscillated between 26.0% and 31.8% over the last ten quarters, suggesting that the company's profitability is highly sensitive to the product mix between high-value ready-to-use solutions and lower-margin bulk glass or engineering-heavy project work.
The compression observed in 2026Q1 to 27.5% from the 30.9% peak in 2025Q4 warrants further investigation into whether this reflects a shift in product mix or increased input costs. The inability to consistently maintain margins above 30% suggests that the company's pricing power may be constrained by the competitive landscape of primary packaging.
Based on the company's reported figures, operating margins have demonstrated significant volatility, peaking at 20.2% in 2024Q4 before declining to 14.2% in 2026Q1, indicating that the firm has yet to achieve the consistent operating leverage required to scale profitability efficiently alongside its revenue base.
The lack of clear operating margin expansion despite revenue growth suggests that fixed costs, particularly those associated with new facility ramps like the Fishers plant, are currently outpacing incremental gross profit gains. This trend implies that management's focus on global capacity expansion is creating a temporary drag on the bottom line that may persist until utilization rates reach critical mass.
Data from recent filings indicates that STVN has maintained relatively disciplined SG&A spending, which has generally hovered around $30 million per quarter, even as the company navigates the complex operational requirements of its global manufacturing footprint and ongoing investments in proprietary drug delivery technologies.
While SG&A remains controlled, the high capital intensity of the business model necessitates constant monitoring of R&D and maintenance expenditures. The company's ability to keep these costs stable while scaling its international operations appears to be a key factor in preventing further margin erosion during periods of revenue volatility.
Quick answers to the most common questions about buying STVN stock.
For fiscal year 2025, Stevanato Group S.p.A. (STVN) reported total revenue of $1.14B. This represents a 112.4% increase compared to $536.5M in 2019.
Stevanato Group S.p.A. (STVN) is profitable, generating $134.3M in net income for the fiscal year ending 2025 with a net profit margin of 11.8%.
Stevanato Group S.p.A. (STVN) reported an operating income of $183.1M, resulting in an operating profit margin of 16.1%. This margin reflects the operational efficiency of the business before interest and taxes.
Stevanato Group S.p.A. (STVN) generated $330.3M in gross profit for the year, representing a gross profit margin of 29.0%. This demonstrates the company's core pricing power and production efficiency.